U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Guidance, Compliance & Regulatory Information (Biologics)
  4. Biologics Post-Market Activities
  5. Lot Release
  6. FDA Plans for Selecting Influenza Virus Strains for Vaccine Composition for the 2025-2026 U.S. Influenza Season
  1. Lot Release

FDA Plans for Selecting Influenza Virus Strains for Vaccine Composition for the 2025-2026 U.S. Influenza Season

The March 13, 2025, meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee on the influenza vaccine strains for the 2025-2026 influenza season in the U.S. has been cancelled. FDA continues to work with federal and international partners and U.S.-licensed influenza vaccine manufacturers to prepare for the upcoming season. FDA, in consultation with our federal partners, will review the available data to make our recommendations to manufacturers of U.S.-licensed influenza vaccines in time for the production of updated vaccines for the 2025-2026 influenza season. We do not anticipate any impact on vaccine supply or timing of availability.

Back to Top